Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Liabilities (2016 - 2025)

Avalo Therapeutics' Total Liabilities history spans 12 years, with the latest figure at $33.4 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 88.75% year-over-year to $33.4 million; the TTM value through Dec 2025 reached $33.4 million, up 88.75%, while the annual FY2025 figure was $33.4 million, 88.75% up from the prior year.
  • Total Liabilities reached $33.4 million in Q4 2025 per AVTX's latest filing, roughly flat from $33.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $224.8 million in Q1 2024 to a low of $13.7 million in Q4 2023.
  • Average Total Liabilities over 5 years is $49.8 million, with a median of $38.4 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: soared 428.95% in 2024, then crashed 92.92% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $57.1 million in 2021, then decreased by 22.49% to $44.3 million in 2022, then tumbled by 69.09% to $13.7 million in 2023, then rose by 29.3% to $17.7 million in 2024, then surged by 88.75% to $33.4 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Total Liabilities are $33.4 million (Q4 2025), $33.6 million (Q3 2025), and $22.0 million (Q2 2025).